Aurora Cannabis Eyes International Growth with Safari Flower Acquisition
Event summary
- Aurora Cannabis reaffirmed its fiscal Q2 2027 guidance for sequential growth in net revenue and adjusted EBITDA.
- The acquisition of Safari Flower Company, EU-GMP certified in July 2026, is expected to contribute incremental revenue and EBITDA.
- Strong performance in Germany and Poland, with #1 market share in Poland, drives international growth expectations.
- UK market expansion underway with recent acquisitions of Internode Pharma and HAP Pharma Limited.
- Aurora reports $149 million in cash as of June 30, 2026, with no debt.
The big picture
Aurora Cannabis is doubling down on its global medical cannabis strategy, leveraging strategic acquisitions to bolster its EU-GMP certified production capacity. The company's focus on high-margin international markets like Germany, Poland, and the UK positions it to capitalize on the growing $9 billion global medical cannabis market. With a strong balance sheet and no debt, Aurora is well-positioned to invest in key markets and create shareholder value.
What we're watching
- Integration Success
- How the Safari Flower acquisition will integrate into Aurora's existing supply network and contribute to revenue growth.
- Regulatory Expansion
- Whether Aurora can sustain its market leadership as regulatory environments in new countries continue to open.
- Market Share Dynamics
- The pace at which Aurora can expand its market share in the UK following recent acquisitions.
Related topics